Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (CRSP 1.05%) first treatment last December, and its successful launch could push the stock much higher.  Investment bank analysts also expect Iovance Biotherapeutics (IOVA 0.13%) to soar in 2025.Before chasing exciting price targets, thou ...